China Vs. Cancer: Coverage For 17 Drugs Unveils Price Pressures, Commercial Battleground
While cancer drug makers generally applaud the rare reimbursement decision in China, some have pointed to mounting and significant pressure to lower prices, while insiders say the real battle has only just began and that translating the coverage into commercial success will take much more effort.
You may also be interested in...
Amid rising cancer incidence in the Asia Pacific region, Roche tells Scrip in this exclusive interview that it is going "beyond the pill" to widen access to drugs in the increasingly important oncology market.
From AI to IPOs, from access models to mobile payments, China’s biopharma sector increasingly became a global leader in biotech financing and digital health innovation in 2018. Here is Scrip's pick of eight key events that captured the major developments in China’s dynamic, highly fluid biopharma commercial scene throughout the year.
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.